Mode
Text Size
Log in / Sign up

Machine learning model predicts central lymph node metastasis in papillary thyroid carcinoma

Machine learning model predicts central lymph node metastasis in papillary thyroid carcinoma
Photo by Bhautik Patel / Unsplash
Key Takeaway
Consider this model as a non-invasive aid for surgical planning in node-negative papillary thyroid carcinoma, noting its retrospective design.

This retrospective cohort study included 710 patients (971 lesions) with clinically node-negative (cN0) T1–T2 papillary thyroid carcinoma. The intervention was an interpretable machine learning model (explainable gradient boosting decision tree) using pathological, ultrasound features, thyroid function, and systemic inflammatory indicators to predict central lymph node metastasis (CLNM).

The model identified five independent predictors: bilateral laterality, tumor size >1.0 cm, age ≤55 years, systemic immune-inflammation index (SII) >449.85, and platelet-to-lymphocyte ratio (PLR) ≤134.88; free triiodothyronine (FT3) was included as an adjunct variable. In the test set, the model had an AUC of 0.830 (95% CI: 0.773–0.887). After correcting for sample overlap, the AUC was 0.812. In an external validation cohort of n=50, the AUC was 0.800.

Safety and tolerability were not reported, as adverse events, serious adverse events, and discontinuations were not reported. The key limitation is the retrospective analysis. The practice relevance is that the model provides a non-invasive and clinically transparent aid for individualized surgical decision-making in cN0 T1–T2 PTC. The certainty is limited by the retrospective design and the need for external validation.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
IntroductionThis study aimed to develop and validate an interpretable machine learning model for preoperative prediction of central lymph node metastasis (CLNM) in patients with clinically node-negative (cN0) T1–T2 papillary thyroid carcinoma (PTC).MethodsA retrospective analysis was conducted on 710 patients (971 lesions), integrating pathological, ultrasound features, thyroid function, and systemic inflammatory indicators. A hierarchical feature selection strategy combining L2 and LASSO regularization was employed to optimize multimodal predictors and reduce overfitting. An explainable gradient boosting decision tree (GBDT) model was constructed and evaluated using calibration curves, decision curve analysis, and SHAP interpretability frameworks.ResultsThe model identified five independent predictors of CLNM: bilateral laterality, tumor size >1.0 cm, age ≤55 years, systemic immune-inflammation index (SII) >449.85, and platelet-to-lymphocyte ratio (PLR) ≤134.88; free triiodothyronine (FT3) was also included as an adjunct variable to enhance performance. The model achieved an AUC of 0.830 (95% CI: 0.773–0.887) in the test set, with robust performance confirmed after correcting for sample overlap (AUC 0.812) and external validation on an independent temporal cohort (n=50, AUC 0.800). The model showed clinical utility across a wide decision threshold range (0–85%).DiscussionThis multimodal, interpretable prediction tool provides a non-invasive and clinically transparent aid for individualized surgical decision-making in cN0 T1–T2 PTC, bridging endocrine and inflammatory biomarkers with machine learning to advance precision thyroid oncology.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.